People ≥ 10 years of age with certain high-risk conditions (including people with anatomical or functional asplenia, persistent complement component deficiency, complement inhibitor use [eg, eculizumab, ravulizumab], microbiologists routinely exposed to N meningitidis), and people identified to be at increased risk because of a meningococcal disease outbreak caused by serogroup B are given a 2-dose series of MenB-4C ≥ 1 month apart or a 3-dose series of MenB-FHbp at 0, 1 to 2, and 6 months (if dose 2 was given at least 6 months after dose 1, dose 3 is not needed).